Announcement • Oct 21

Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. (NasdaqGM:TALS) from a group of shareholders in a reverse merger transaction.

Tourmaline Bio, Inc. entered into a definitive agreement to acquire Talaris Therapeutics, Inc. (NasdaqGM:TALS) from a group of shareholders for approximately $260 million in a reverse merger transaction on June 22, 2023. Subject to the terms and conditions of the merger agreement, at the closing of the Merger and related transactions, (a) each then-outstanding share of Tourmaline common stock will be converted into the right to receive a number of shares of Talaris common stock calculated in accordance with the merger agreement (the “Exchange Ratio”) and (b) each then-outstanding option to purchase Tourmaline common stock will be converted into an option to purchase Talaris common stock, subject to adjustment as set forth in the Merger Agreement. Based on Talaris’ and Tourmaline’s capitalization as of August 25, 2023, the Exchange Ratio was estimated to be equal to 0.771 shares of Talaris common stock for each share of Tourmaline common stock, which is subject to adjustments based upon Talaris’ net cash at the closing and the aggregate proceeds from the sale of Tourmaline common stock in the Tourmaline pre-closing financing. As on October 6, 2023, Talaris disclosed the final Exchange Ratio will be 0.8055. As of October 10, 2023, Pursuant to the Merger Agreement, the final Exchange Ratio will be 0.7977. Under the Exchange Ratio formula in the merger agreement, upon the Closing, on a pro forma basis and based upon the number of shares of Talaris common stock expected to be issued in the Merger, pre-Merger Tourmaline stockholders will own approximately 59.4% of the combined company, the pre-Merger Talaris stockholders will own approximately 21.3% of the combined company on a fully diluted basis using treasury stock method and investors who are issued shares of Tourmaline common stock in the financing transaction described below will own approximately 19.3% of the combined company on a fully diluted basis using treasury stock method. The Exchange Ratio, and related pro forma ownership, will be adjusted to the extent that Talaris’ net cash at Closing is less than $62,437,500 or greater than $72,562,500. Upon termination of the Merger Agreement under specified circumstances, Talaris may be required to pay Tourmaline a termination fee of $5.0 million and/or reimburse Tourmaline’s expenses up to a maximum of $500,000, and Tourmaline may be required to pay Talaris a termination fee of $7.1 million and/or reimburse Talaris’ expenses up to a maximum of $500,000. Upon completion of the Merger, the combined company will operate under the name Tourmaline Bio, Inc. and trade on the Nasdaq under the ticker symbol “TRML.” In addition, Talaris anticipates making a cash dividend of up to approximately $64.8 million to its stockholders prior to the closing of the Merger. Tourmaline stockholders immediately prior to the Merger (including Tourmaline stockholders issued shares in the private placement) are expected to own approximately 78.7% of the combined company and Talaris stockholders immediately prior to the Merger are expected to own approximately 21.3% of the combined company, each on a fully diluted basis. The percentage of the combined company that each company’s former stockholders are expected to own may be adjusted based on Talaris’ net cash at closing (subject to a collar) and the proceeds from the sale of certain of Talaris’ legacy assets prior to closing. Following the Merger, the combined company will be led by current members of the Tourmaline leadership team, including: Sandeep Kulkarni, MD, Chief Executive Officer; Yung Chyung, MD, Chief Medical Officer; Brad Middlekauff, JD, Chief Business Officer and General Counsel; Susan Dana Jones, Chief Technology Officer; Ryan Iarrobino, Senior Vice President, Product Development; Kevin Johnson, Chief Regulatory Officer, Dora Rau, Senior Vice President, Head of Quality. The merger agreement provides that the Board of Directors of the combined company will be composed of seven board members; five board members, including the CEO of Tourmaline, will be named by Tourmaline and two board members will be named by Talaris. As on October 6, 2023, Talaris disclosed that On September 2, 2023, the Talaris Board designated Mark D. McDade and Sapna Srivastava continue as directors of the combined company following the closing of the transaction they will be compensated as a non-employee director of the combined company pursuant to the non-employee director compensation policy. The closing of the merger is subject to various conditions including the registration statement of which this proxy statement/prospectus forms a part shall have become effective; Nasdaq must have approved the listing of additional shares of Talaris common stock, including the shares to be issued in connection with the merger; each lock-up agreement to be entered into by certain of Tourmaline’s stockholders will continue to be in full force; each lock-up agreement to be entered into by certain of Tourmaline’s stockholders will continue to be in full force; approvals by stockholders of Tourmaline and Talaris, regulatory approvals, and other customary closing conditions. The merger has been unanimously approved by the Board of Directors of both companies and both Boards of Directors have recommended that their respective stockholders approve the matters regarding the Merger. In connection with the Merger, directors, officers and certain stockholders of each of Tourmaline and Talaris have executed support agreements, pursuant to the terms of which they have agreed to vote all of their shares of capital stock in favor of the Merger or the issuance of Talaris shares in the Merger, as applicable. The merger is expected to close in the fourth quarter of 2023. On June 22, 2023, Tourmaline entered into a securities purchase agreement with certain investors, pursuant to which Tourmaline agreed to sell shares of Tourmaline common stock for an aggregate purchase price of approximately $75 million (the “Pre-Closing Financing”) immediately prior to the Closing. As on October 6, 2023, in connection with the merger, Talaris Board of Directors declared a special dividend of $1.5118 per share of Talaris common stock, which will be payable in cash. The Special Dividend will not exceed an amount equal to $67.5 million, net of the Aggregate Cash Amount. As of October 10, 2023, transaction is expected to close on October 19, 2023. As of October 17, 2023, the shareholders of Talaris Therapeutics, Inc. approved the merger.Jefferies, Piper Sandler, Guggenheim Securities, and Truist Securities are serving as placement agents to Tourmaline in connection with the private placement and Brandon W. Fenn and William Sorabella of Cooley LLP are serving as legal counsel to Tourmaline in connection with the private placement and the Merger. Leerink Partners LLC is serving as exclusive financial advisor and fairness opinion provider to Talaris Board and Richard Hoffman, John T. Haggerty and Tevia K. Pollard of Goodwin Procter LLP are serving as legal counsel to Talaris. Computershare Trust Company, N.A. acted as transfer agent and Mediant Communications Inc. acted as proxy solicitor to Talaris for a fee of approximately $5,300 plus reimbursement of out-of-pocket expenses. In connection with Leerink Partners’ services as financial advisor to Talaris, Talaris has agreed to pay Leerink Partners an aggregate fee of $2.5 million, $500,000 of which became payable upon the rendering by Leerink Partners of the opinion, and the remainder of which is payable contingent upon consummation of the merger.Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. (NasdaqGM:TALS) from a group of shareholders in a reverse merger transaction on October 19, 2023. The combined company will operate under the name, Tourmaline Bio, Inc., and its shares are expected to begin trading on the Nasdaq Global Market on October 20, 2023 under the ticker symbol “TRML”. Concurrent with the merger, Tourmaline completed a $75 million private placement with a syndicate of new and existing institutional life sciences investors including Acuta Capital Partners, Affinity Asset Advisors, Braidwell LP, Cowen Healthcare Investments, Deep Track Capital, Great Point Partners, LLC, KVP Capital, Logos Capital, Paradigm BioCapital, Qiming Venture Partners USA, RA Capital Management, LP, StemPoint Capital LP, TCGX, Vivo Capital, and other undisclosed investors. Following the transactions, Tourmaline’s cash, cash equivalents and investments of approximately $218 million, before payment of final transaction-related expenses, is expected to fund operations through 2026.

Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Historical stock prices
Current Share Price	US$47.98
52 Week High	US$48.27
52 Week Low	US$11.56
Beta	1.58
1 Month Change	-0.37%
3 Month Change	116.81%
1 Year Change	81.19%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	340.18%

	TRML	US Biotechs	US Market
7D	0.02%	1.2%	2.1%
1Y	81.2%	41.9%	30.6%

TRML volatility
TRML Average Weekly Movement	17.1%
Biotechs Industry Average Movement	10.6%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

TRML fundamental statistics
Market cap	US$1.24b
Earnings (TTM)	-US$88.47m
Revenue (TTM)	n/a

TRML income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$88.47m
Earnings	-US$88.47m

Earnings per share (EPS)	-3.43
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

Data	Last Updated (UTC time)
Company Analysis	2025/10/29 08:24
End of Day Share Price	2025/10/27 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

This company has been acquired

Tourmaline Bio (TRML) Stock Overview

Risk Analysis

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Tourmaline Bio, Inc. Competitors

Immatics

Dynavax Technologies

Ardelyx

YD Bio

Price History & Performance

Recent News & Updates

Tourmaline Bio Requests Nasdaq Global Select Market to Suspend the Shares from Trading Effective October 28, 2025 and Remove the Shares from Listing on Nasdaq

Tourmaline Bio, Inc. Announces Management and Committee Changes

Novartis AG (SWX:NOVN) completed the acquisition of 92.94% in Tourmaline Bio, Inc. (NasdaqGS:TRML).

CFO & Treasurer exercised options to buy US$689k worth of stock.

Price target decreased by 14% to US$48.39

Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action

Recent updates

Tourmaline Bio Requests Nasdaq Global Select Market to Suspend the Shares from Trading Effective October 28, 2025 and Remove the Shares from Listing on Nasdaq

Tourmaline Bio, Inc. Announces Management and Committee Changes

Novartis AG (SWX:NOVN) completed the acquisition of 92.94% in Tourmaline Bio, Inc. (NasdaqGS:TRML).

CFO & Treasurer exercised options to buy US$689k worth of stock.

Price target decreased by 14% to US$48.39

Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action

Novartis AG (SWX:NOVN) entered into an agreement to acquire Tourmaline Bio, Inc. (NasdaqGS:TRML) for $1.2 billion.

Tourmaline Bio (NASDAQ:TRML) Is In A Good Position To Deliver On Growth Plans

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 Transit Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-Reactive Protein and Chronic Kidney Disease

Tourmaline Bio, Inc., Annual General Meeting, Jun 04, 2025

We're Not Very Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Rate

New major risk - Revenue and earnings growth

Tourmaline Bio, Inc. Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

Tourmaline Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

High number of new and inexperienced directors

Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting

Tourmaline Bio, Inc. Announces Resignation of Yung Chyung as Chief Medical Officer,Effective October 31, 2024

Tourmaline Bio, Inc. Announces Formation of Cardiovascular Scientific Advisory Board

New minor risk - Share price stability

Tourmaline Bio, Inc. Announces the Promotion of Ryan Robinson to Chief Financial Officer

Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish

Tourmaline Bio, Inc. has filed a Follow-on Equity Offering.

Tourmaline Bio: Time For A Pause

Tourmaline Bio, Inc. Appoints Clay Siegall to Serve as a Director

Tourmaline Bio, Inc. Announces Resignation of Cariad Chester as Member of the Board of Directors

Co-Founder recently bought US$68k worth of stock

Co-Founder recently bought US$111k worth of stock

Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. (NasdaqGM:TALS) from a group of shareholders in a reverse merger transaction.

Tourmaline Bio, Inc. entered into a definitive agreement to acquire Talaris Therapeutics, Inc. (NasdaqGM:TALS) from shareholders in a reverse merger transaction.

Shareholder Returns

Price Volatility

About the Company

Tourmaline Bio, Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources